← Patent-cliff monitor small molecule RYTELO IMETELSTAT SODIUM
Loss of exclusivity June 2039 latest FDA-listed patent expiry
Company Geron → See this company's full patent-cliff portfolio Drug detail Brand name RYTELO Active ingredient IMETELSTAT SODIUM Strength EQ 47MG BASE/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval June 2024 Marketing status RX
Listed patents Patent Expires Type 12171778 June 2039 use U-3956 12442000 March 2033 use U-3956 9375485 March 2033 use U-3956 7494982 December 2026 substance, product 9388416 September 2026 use U-3956 9388415 September 2026 use U-3956
Regulatory exclusivity Code Expires ODE-482 June 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.